Evolving Dilemmas and Management of Portopulmonary Hypertension

ABSTRACT

Portopulmonary hypertension (POPH) is an uncommon but serious pulmonary vascular consequence of portal hypertension. Untreated, POPH results in right heart failure and death, regardless of the severity of portal hypertension. The existence of moderate to severe POPH has posed higher risk for orthotopic liver transplantation (OLT). New and evolving medical approaches may change the natural history of this disorder. Such approaches include administration of prostacyclins, endothelin receptor antagonists, and phosphodiesterase inhibitors. Administration may involve 24-hour continuous infusions, periodic inhaled, and oral routes. Liver transplantation in patients with moderate to severe POPH is problematic. Aside from patients being denied OLT specifically because of POPH, intraoperative death has occurred and unacceptable mortality during the transplant hospitalization has been reported. Finally, guidelines are evolving concerning which patients will benefit from the combination of evolving medical therapies and OLT. Whether the natural history of POPH can be dramatically changed remains an optimistic conjecture.

Liver transplantation - echocardiography - pulmonary hypertension

REFERENCES

• 1 Krowka M J. Hepatopulmonary syndrome and portopulmonary hypertension: distinctions and dilemmas.  Hepatology. 1997;  25 1282-1284
• 2 Herve P, Lebrec D, Brenot F et al.. Pulmonary vascular disorders in portal hypertension.  Eur Respir J. 1998;  11 1153-1166
• 3 Rodriguez-Roisin R, Krowka M J, Herve P et al.. Pulmonary-hepatic vascular disorders: a task force report.  Eur Respir J. 2004;  24 861-880
• 4 Krowka M J, Frantz R P, McGoon M D et al.. Improvement in pulmonary hemodynamics during intravenous epoprostenol (prostacyclin): a study of 15 patients with moderate to severe portopulmonary hypertension.  Hepatology. 1999;  30 641-648
• 5 Edwards B S, Weir E K, Edwards W D et al.. Coexistent pulmonary and portal hypertension: morphologic and clinical features.  J Am Coll Cardiol. 1987;  10 1233-1288
• 6 Krowka M J, Edwards W D. The spectrum of pathology in portopulmonary hypertension.  Liver Transpl. 2000;  6 241-242
• 7 Hadengue A, Benhayoun M K, Lebrec D et al.. Pulmonary hypertension complicating portal hypertension: prevalence and relation to splanchnic hemodynamics.  Gastroenterology. 1991;  100 520-528
• 8 Robalino B D, Moodie D S. Association between primary pulmonary hypertension and portal hypertension: analysis of its pathophysiology and clinical, laboratory and hemodynamic manifestations.  J Am Coll Cardiol. 1991;  17 492-498
• 9 Kawut S M, Taichman D B, Alrya V N et al.. Hemodynamics and survival of patients with portopulmonary hypertension.  Liver Transpl. 2005;  11 1107-1111
• 10 Swanson K L, McGoon M D, Krowka M J. Survival in portopulmonary hypertension and orthotopic liver transplantation [abstract].  Liver Transpl. 2005;  11 C-71
• 11 Simonneau G, Galie N, Rubin L J et al.. Clinical classification of pulmonary hypertension.  J Am Coll Cardiol. 2004;  43 5S-12S
• 12 Mantz Jr F A, Craige E. Portal axis thrombosis with spontaneous portacaval shunt and resultant cor pulmonale.  AMA Arch Pathol. 1951;  52 91-97
• 13 Senior R M, Britton R C, Turino G M et al.. Pulmonary hypertension associated with cirrhosis of the liver and with portacaval shunts.  Circulation. 1968;  37 88-96
• 14 Lebrec D, Capron J P, Dhumeaux D, Benhamou J P. Pulmonary hypertension complicating portal hypertension.  Am Rev Respir Dis. 1979;  120 849-856
• 15 Kuo P C, Plotkin J S, Johnson L B et al.. Distinctive clinical features of portopulmonary hypertension.  Chest. 1997;  112 980-986
• 16 Hoeper M M, Rubin L J. Update in pulmonary hypertension 2005.  Am J Respir Crit Care Med. 2006;  173 499-503
• 17 Donovan C L, Marcovitz P A, Punch J D et al.. Two-dimensional and dobutamine stress echocardiography in the preoperative assessment of patients with end-stage liver disease prior to orthotopic liver transplantation.  Transplantation. 1996;  61 1180-1188
• 18 Kim W R, Krowka M J, Plevak D J et al.. Accuracy of Doppler echocardiography in the assessment of portopulmonary hypertension in liver transplant candidates.  Liver Transpl. 2000;  6 453-458
• 19 Cotton C L, Gandhi S, Vaitkus P T et al.. Role of echocardiography in detecting portopulmonary hypertension in liver transplant candidates.  Liver Transpl. 2002;  8 1051-1054
• 20 Krowka M J, Swanson K L, Frantz R P et al.. Screening for portopulmonary hypertension and results of right heart catheterization [abstract].  Liver Transpl. 2005;  11 C-83
• 21 Benjaminov F S, Prentice M, Sniderman K W et al.. Portopulmonary hypertension in decompensated cirrhosis and refractory ascites.  Gut. 2003;  52 1355-1362
• 22 Castro M, Krowka M J, Schroeder D R et al.. Frequency and clinical implications of increased pulmonary artery pressures in liver transplant patients.  Mayo Clin Proc. 1996;  71 543-551
• 23 Wiesner R, Edwards E, Freeman R et al.. Model for end-stage liver disease (MELD) and allocation of liver donors.  Gastroenterology. 2003;  124 91-96
• 24 Azoulay D, Castaing Y, Dennison A et al.. Transjugular intrahepatic portosystemic shunt worsens the hyperdynamic circulatory state of the cirrhotic patient.  Hepatology. 1994;  19 129-132
• 25 Van der Linden P, Le Moine O, Ghysels M et al.. Pulmonary hypertension after transjugular intrahepatic portosystemic shunt effects on the right ventricle.  Hepatology. 1996;  23 982-987
• 26 Murray K F, Carithers R L. AASLD practice guidelines: evaluation of the patients for liver transplantation.  Hepatology. 2005;  41 1407-1432
• 27 Kuo P C, Johnson L B, Plotkin J S et al.. Continuous intravenous infusion of epoprostenol for the treatment of portopulmonary hypertension.  Transplantation. 1997;  63 604-606
• 28 McLaughlin V V, Genthner R N, Panella M M et al.. Compassionate use of continuous prostacyclin in the management of secondary pulmonary hypertension.  Ann Intern Med. 1999;  130 740-743
• 29 Hoeper M M, Halank M, Marx C et al.. Bosentan for the treatment of portopulmonary hypertension.  Eur Respir J. 2005;  25 502-508
• 30 Plotkin J S, Kuo P C, Rubin L J et al.. Successful use of chronic epoprostenol as a bridge to liver transplantation in severe portopulmonary hypertension.  Transplantation. 1998;  65 457-459
• 31 Tan H P, Markowitz J S, Montgomery R A et al.. Liver transplantation in patients with severe portopulmonary hypertension treated with preoperative chronic intravenous epoprostenol.  Liver Transpl. 2001;  7 745-749
• 32 Kett D H, Acost R C, Campos M A et al.. Recurrent portopulmonary hypertension after liver transplantation: management with epoprostenol and resolution after retransplantation.  Liver Transpl. 2001;  7 645-648
• 33 Minder S, Fishler M, Muelihaupt B et al.. Intravenous iloprost bridging to orthotopic liver transplantation in portopulmonary hypertension.  Eur Respir J. 2004;  24 703-707
• 34 Clift P F, Bramhill S, Isaac J L. Successful treatment of severe portopulmonary hypertension after liver transplantation by bosentan.  Transplantation. 2004;  77 1774-1776
• 35 Kuntzen C, Golberg V, Gerbes A L. Use of a mixed endothelin receptor antagonist in portopulmonary hypertension: a safe and effective therapy?.  Gastroenterology. 2005;  128 164-168
• 36 Molnar C, Alber H, Colleselli D et al.. Successful switch from inhaled iloprost to oral bosentan in portopulmonary hypertension associated with liver cirrhosis.  Wien Klin Wochenschr. 2004;  116 627-630
• 37 Kahler C M, Graziadei I, Wiedermann C J et al.. Novel use of sildenafil in the treatment of portopulmonary hypertension.  Wien Klin Wochenschr. 2000;  112 637-640
• 38 Makisalo H, Koivusalo A, Vakkuri A et al.. Sildenafil for portopulmonary hypertension in a patient undergoing liver transplantation.  Liver Transpl. 2004;  10 945-950
• 39 Kao P N. Simvastatin treatment for pulmonary hypertension.  Chest. 2005;  127 1446-1452
• 40 Sulica R, Emre S, Poon M. Medical management of portopulmonary hypertension and right heart failure prior to living-related liver transplantation.  Congest Heart Fail. 2004;  10 192-194
• 41 Henriksen J H, Gotz J P, Fuglsang S et al.. Increased circulating pro-brain natriuretic peptide (proBNP) and brain natriuretic peptide (BNP) in patients with cirrhosis: relation to cardiovascular dysfunction and severity of disease.  Gut. 2003;  52 1511-1517
• 42 Provencher S, Herve P, Jais X et al.. Deleterious effects of beta-blockers on exercise capacity and hemodynamics in patients with portopulmonary hypertension.  Gastroenterology. 2006;  130 120-126
• 43 Krowka M J, Mandell M S, Ramsay M AE et al.. Hepatopulmonary syndrome and portopulmonary hypertension: a report of the multicenter liver transplant database.  Liver Transpl. 2004;  10 174-182
• 44 Schott R, Chaouat A, Launoy A et al.. Improvement of pulmonary hypertension after liver transplantation.  Chest. 1999;  115 1748-1749
• 45 De Wolf A M, Gasior T, Kang Y. Pulmonary hypertension in a patient undergoing liver transplantation.  Transplant Proc. 1991;  23 2000-2001
• 46 Krowka M J, Plevak D J, Findlay J Y et al.. Pulmonary hemodynamics and perioperative cardiopulmonary mortality in patients with portopulmonary hypertension undergoing liver transplantation.  Liver Transpl. 2000;  6 443-450
• 47 Ramsay M AE, Simpson B R, Nguyen A T et al.. Severe pulmonary hypertension in liver transplant candidates.  Liver Transpl Surg. 1997;  3 494-500
• 48 Starkel P, Vera A, Gunson B, Mutimer D. Outcome of liver transplantation for patients with pulmonary hypertension.  Liver Transpl. 2002;  8 382-388
• 49 Pirenne J, Verlede G, Nevens F et al.. Combined liver and heart-lung transplantation in liver transplant candidates with refractory portopulmonary hypertension.  Transplantation. 2002;  73 140-142
• 50 Urashima Y, Tojimbara T, Nakajima I et al.. Living related liver transplantation for biliary atresia with portopulmonary hypertension.  Transplant Proc. 2004;  36 2237-2238
• 51 Kikuchi H, Ohkoohchi N, Orli T et al.. Living-related liver transplantation in patients with pulmonary vascular disease.  Transplant Proc. 2000;  32 2177-2178
• 52 Martinez-Palli G, Barbera J A, Taura P et al.. Severe portopulmonary hypertension after liver transplantation in a patient with preexisting hepatopulmonary syndrome.  J Hepatol. 1999;  31 1075-1079
• 53 Kaspar M D, Ramsay M A, Shuey Jr C B et al.. Severe pulmonary hypertension and amelioration of hepatopulmonary syndrome after liver transplantation.  Liver Transpl Surg. 1998;  4 177-179
• 54 Aucejo F, Miller C, Vogt D et al.. Portopulmonary hypertension following liver transplantation in patients with antecedent hepatopulmonary syndrome.  Liver Transpl. 2006;  , In press
• 55 Mandell M S, Groves B M, Duke J. Progressive plexogenic pulmonary hypertension following liver transplantation.  Transplantation. 1995;  59 1488-1490
• 56 Koneru B, Fisher A, Wilson D J et al.. De novo diagnosis of portopulmonary hypertension following liver transplantation.  Am J Transplant. 2002;  2 883-886
• 57 Mal H, Burgiere O, Durand F et al.. Pulmonary hypertension following hepatopulmonary syndrome.  J Hepatol. 1999;  31 360-364
• 58 Shah T, Isaac J, Adams D et al.. Development of hepatopulmonary syndrome and portopulmonary hypertension in a paediatric liver transplant recipient.  Pediatr Transplant. 2005;  9 127-131
• 59 Jones F D, Kuo P C, Johnson L B et al.. The coexistence of portopulmonary hypertension and hepatopulmonary syndrome.  Anesthesiology. 1999;  90 626-629
• 60 Tasaka S, Kanazawa M, Nakamura H et al.. An autopsied case of primary pulmonary hypertension complicated by hepatopulmonary syndrome.  Nihon Kyobu Shikkan Gakkai Zasshi. 1995;  33 90-94
• 61 Castro P F, Bourge R C, McGiffin D C. Intrapulmonary shunting in primary pulmonary hypertension: an observation in two patients treated with epoprostenol sodium.  Chest. 1998;  114 334-336
• 62 Cool C D, Stewart J S, Werahera P et al.. Three-dimensional reconstruction of pulmonary arteries in plexiform pulmonary hypertension.  Am J Pathol. 1999;  155 411-419
• 63 Sussman N, Frost A, Kaza V et al.. Successful liver transplantation following treatment of portopulmonary hypertension [abstract].  Hepatology. 2005;  42 327A
• 64 Schermuly R T, Dony E, Ghofrani H A et al.. Reversal of experimental pulmonary hypertension by PDGF inhibition.  J Clin Invest. 2005;  115 2811-2821